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background: Earlier meta-analyses demonstrated significant reduction in major adverse cardiac events (MACE) with dipeptidyl peptidase 4 
inhibitor (DPPI), as compared to placebo or alternative anti-diabetic agents. However, the recently published phase 4 trials (SAVOR TIMI-53, 
EXAMINE) failed to demonstrate any significant differences in MACE between DPPI and placebo. We performed an updated meta-analysis of 
randomized controlled trials (RCT) to investigate the differences in outcomes between DPPI and placebo/ alternative agents
methods: We searched the Medline, EMBASE and Cochrane databases for relevant phase 3/ phase 4 RCTs. Unpublished trials with results 
available on national clinical trials (NCT) register were also included.
results: A total of 82 RCTs including 73678 patients were included. We did not observe any significant difference in the pooled odds of 
cardiovascular death, MI or stroke in the composite DPPI arm as compared to the control arm. Similarly, the pooled odds of all-cause death and 
MACE were statistically similar between the two groups. Due to a larger sample size and a longer duration of follow-up, the recently published RCTs 
had a considerably larger contribution to the pooled estimates in our meta-analysis, driving the updated pooled estimates towards null for all 
clinical outcomes assessed (Figure).
conclusions: DPPI use was not associated with increased incidence of cardiovascular mortality, MI, stroke or MACE as compared to placebo or 
alternative anti-diabetic agents.
 
